Would it be possible for BOT management to seek exemption from a phase iii trial?
Epidiolex already has FDA approval with a CBD active...
and it wouldn't be the first time, Painkiller "Rexista RX" didn't need to go through phase iii because it was deemed "bioequivalent" to the already FDA approved OxyContin.
Thoughts?
Would it be possible for BOT management to seek exemption from a...
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
-0.005(1.37%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 37.0¢ | 36.0¢ | $391.8K | 1.080M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 160000 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 11013 | 2 |
View Market Depth
| Last trade - 16.10pm 29/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
